Glucosamine and chondroitin are supplements that are often, but not always, used in combination for arthritis and joint pain. Multiple studies have suggested that glucosamine and chondroitin may be associated with reduced risk of several diseases, as well as all-cause, cancer- and respiratory disease-specific mortality.
Methods:
Nationally representative data from the National Health and Nutrition Examination Survey (NHANES) were used to further evaluate the association between glucosamine and chondroitin with mortality. Participants include 38,021 adults, ages 20+ years and older, who completed the detailed NHANES between 1999 and 2014. Participants were followed for death through linkage with the National Death Index through the end of 2015, over which time 4905 deaths occurred. Adjusted hazard ratios (HRs) for overall and cause-specific mortality were estimated using Cox regression models.
Results:
Despite glucosamine and chondroitin use appearing to be inversely associated with mortality in the minimally adjusted models, no association was observed in multivariable models (glucosamine: HR = 1.02; 95% confidence interval [CI]: 0.86–1.21, chondroitin: HR = 1.04, 95% CI: 0.87–1.25). No association with cancer mortality or other mortality rate was observed after multivariable adjustment. There was a suggestive, nonsignificant inverse association for cardiovascular-specific mortality (glucosamine HR = 0.72; 95% CI: 0.46–1.15, chondroitin: HR = 0.76; 95% CI: 0.47–1.21).
Conclusion:
The lack of significant relationship between glucosamine and chondroitin use and all-cause or cause-specific mortality after adjusting extensively for multiple covariates in this nationally representative adult population was in contrast to prior literature. Given the limited power to explore the cause-specific mortality, future well-powered studies will be needed to better understand the potential association with cardiovascular-specific mortality.
Get full access to this article
View all access options for this article.
References
1.
QatoDM, AlexanderGC, ContiRM, et al.Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA, 2008; 300(24):2867–2878; doi: 10.1001/jama.2008.892
2.
KantorED, RehmCD, DuM, et al.Trends in dietary supplement use among US adults from 1999–2012. JAMA, 2016; 316(14):1464–1474; doi: 10.1001/jama.2016.14403
3.
AndersonJW, NicolosiRJ, BorzellecaJF. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol, 2005; 43(2):187–201; doi: 10.1016/j.fct.2004.11.006.
4.
RindoneJP, HillerD, CollacottE, et al.Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med, 2000; 172(2):91–94.
5.
ReginsterJ-Y, VeroneseN. Highly purified chondroitin sulfate: A literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res, 2021; 33(1):37–47; doi: 10.1007/s40520-020-01643-8
6.
GrahamDJ, CampenD, HuiR, et al.Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet, 2005; 365(9458):475–481; doi: 10.1016/S0140-6736(05)17864-7
7.
BombardierC, LaineL, ReicinA, et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 2000; 343(21):1520–1528; doi: 10.1056/NEJM200011233432103
8.
JordanKM, ArdenNK, DohertyM, et al.EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2003; 62(12):1145–1155; doi: 10.1136/ard.2003.011742
9.
KerrSJ, RowettDS, SayerGP, et al.All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: A longitudinal study. Br J Clin Pharmacol, 2011; 71(6):936–942; doi: 10.1111/j.1365-2125.2010.03702.x
10.
GislasonGH, RasmussenJN, AbildstromSZ, et al.Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med, 2009; 169(2):141–149; doi: 10.1001/archinternmed.2008.525
11.
OlsenA-MS, FosbølEL, LindhardsenJ, et al.Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: A nationwide cohort study. Circulation, 2012; 126(16):1955–1963; doi: 10.1161/CIRCULATIONAHA.112.112607
12.
McAlindonTE, LaValleyMP, GulinJP, et al.Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA, 2000; 283(11):1469–1475; doi: 10.1001/jama.283.11.1469
13.
Glyn-JonesS, PalmerAJR, AgricolaR, et al.Osteoarthritis. Lancet, 2015; 386(9991):376–387; doi: 10.1016/S0140-6736(14)60802-3
14.
Herrero-BeaumontG, IvorraJAR, del Carmen TrabadoM, et al.Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum, 2007; 56(2):555–567; doi: 10.1002/art.22371
15.
WandelS, JüniP, TendalB, et al.Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis. BMJ, 2010; 341:c4675; doi: 10.1136/bmj.c4675
16.
CleggDO, RedaDJ, HarrisCL, et al.Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med, 2006; 354(8):795–808; doi: 10.1056/NEJMoa052771
17.
KantorE, LampeJ, PetersU, et al.Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control, 2013; 24(6):1137–1146; doi: 10.1007/s10552-013-0192-2
18.
SatiaJA, LittmanA, SlatoreCG, et al.Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins And Lifestyle (VITAL) Study. Cancer Epidemiol Biomarkers Prev, 2009; 18(5):1419–1428; doi: 10.1158/1055-9965.EPI-09-0038
19.
BellGA, KantorED, LampeJW, et al.Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol, 2012; 27(8):593–603; doi: 10.1007/s10654-012-9714-6
20.
LiZ-H, GaoX, ChungVC, et al.Associations of regular glucosamine use with all-cause and cause-specific mortality: A large prospective cohort study. Ann Rheum Dis, 2020; 79(6):829–836; doi: 10.1136/annrheumdis-2020-217176
21.
MaH, LiX, SunD, et al.Association of habitual glucosamine use with risk of cardiovascular disease: Prospective study in UK Biobank. BMJ, 2019; 365:l1628; doi: 10.1136/bmj.l1628
22.
KingDE, XiangJ. Glucosamine/chondroitin and mortality in a US NHANES cohort. J Am Board Fam Med, 2020; 33(6):842–847; doi: 10.3122/jabfm.2020.06.200110
23.
BraskyTM, LampeJW, SlatoreCG, et al.Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control, 2011; 22(9):1333–1342; doi: 10.1007/s10552-011-9806-8
24.
PocobelliG, KristalAR, PattersonRE, et al.Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr, 2010; 91(6):1791–1800; doi: 10.3945/ajcn.2009.28639
25.
KantorED, NewtonCC, GiovannucciEL, et al.Glucosamine use and risk of colorectal cancer: Results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control, 2018; 29(3):389–397; doi: 10.1007/s10552-018-1003-6
26.
KantorED, O'ConnellK, LiangPS, et al.Glucosamine use and risk of colorectal cancer: Results from UK Biobank. Cancer Epidemiol Biomarkers Prev, 2022; 31(3):647–653; doi: 10.1158/1055-9965.EPI-21-1171
27.
KantorED, ZhangX, WuK, et al.Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study. Int J Cancer, 2016; 139(9):1949–1957; doi: 10.1002/ijc.30250
28.
LiG, ZhangX, LiuY, et al.Relationship between glucosamine use and the risk of lung cancer: Data from a nationwide prospective cohort study. Eur Respir J, 2022; 59(3):2101399; doi: 10.1183/13993003.01399-2021
29.
LargoR, Alvarez-SoriaMA, Díez-OrtegoI, et al.Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage, 2003; 11(4):290–298; doi: 10.1016/S1063-4584(03)00028-1
30.
WuY-L, KouYR, OuH-L, et al.Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol, 2010; 635(1):219–226; doi: 10.1016/j.ejphar.2010.02.044
31.
YomogidaS, HuaJ, SakamotoK, et al.Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-α-stimulated human colonic epithelial HT-29 cells. Int J Mol Med, 2008; 22(2):205–211; doi: 10.3892/ijmm_00000010
32.
GouzeJ-N, BordjiK, GulbertiS, et al.Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: Influence of glucosamine on interleukin-1β–mediated effects in rat chondrocytes. Arthritis Rheum, 2001; 44(2):351–360; doi: 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.0.CO;2-M
33.
HuaJ, SakamotoK, KikukawaT, et al.Evaluation of the suppressive actions of glucosamine on the interleukin-1β-mediated activation of synoviocytes. Inflamm Res, 2007; 56(10):432–438; doi: 10.1007/s00011-007-7020-7
34.
RajapakseN, KimM-M, MendisE, et al.Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-κB signaling. Immunology, 2008; 123(3):348–357; doi: 10.1111/j.1365-2567.2007.02683.x
35.
KantorED, LampeJW, NavarroSL, et al.Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med, 2014; 20(6):479–485; doi: 10.1089/acm.2013.0323
36.
KantorED, LampeJW, VaughanTL, et al.Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol, 2012; 176(11):1002–1013; doi: 10.1093/aje/kws186
37.
NavarroSL, WhiteE, KantorED, et al.Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One, 2015; 10(2):e0117534; doi: 10.1371/journal.pone.0117534
38.
NakamuraH, NishiokaK. Effects of glucosamine/chondroitin supplement on osteoarthritis: Involvement of PGE2 and YKL-40. J Rheum Jt Surg, 2002; 21(2):175–184; doi: 10.11551/jsjd1982.21.175
39.
MarsikC, Kazemi-ShiraziL, SchickbauerT, et al.C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem, 2008; 54(2):343–349; doi: 10.1373/clinchem.2007.091959
40.
SullivanDH, RobersonPK, JohnsonLE, et al.Association between inflammation-associated cytokines, serum albumins, and mortality in the elderly. J Am Med Dir Assoc, 2007; 8(7):458–463; doi: 10.1016/j.jamda.2007.04.004
41.
KantorED, O'ConnellK, DuM, et al.Glucosamine and chondroitin use in relation to C-reactive protein concentration: Results by supplement form, formulation, and dose. J Altern Complement Med, 2021; 27(2):150–159; doi: 10.1089/acm.2020.0283
42.
Anonymous. NCHS Data Linkage—Mortality Data. 2022. Available from: https://www.cdc.gov/nchs/data-linkage/mortality.htm [Last accessed: March4, 2022].
43.
National Center for Health Statistics (U.S.), (ed). National Health and Nutrition Examination Survey: Analytic Guidelines, 1999–2010. Vital and Health Statistics. Series 2 Number 161. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics: Hyattsville, MD; 2013.
44.
Anonymous. Profile of Older Americans | ACL Administration for Community Living. n.d. Available from: https://acl.gov/aging-and-disability-in-america/data-and-research/profile-older-americans [Last accessed: July20, 2022].
45.
SuissaK, HudsonM, SuissaS. Glucosamine and lower mortality and cancer incidence: Selection bias in the observational studies. Pharmacoepidemiol Drug Saf, 2022; 31(12):1272–1279; doi: 10.1002/pds.5535
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
